CareDx, Inc. 8-K

What Happened

• CareDx, Inc. announced two completed transactions in an 8-K filed July 7, 2026. On June 30, 2026, the company closed the sale of its wholly owned Swedish subsidiary CareDx AB and certain kitted laboratory products and related software to Eurobio Scientific S.A. for $171.7 million in cash (subject to customary working capital, cash and indebtedness adjustments).
• On July 1, 2026, CareDx completed the acquisition of Naveris, Inc. via a merger in which Naveris became a wholly owned subsidiary. The initial cash consideration paid was $161.8 million (subject to customary adjustments); Naveris equityholders may receive up to an additional $100.0 million in cash contingent on revenue-based milestones for fiscal years ending December 31, 2026 and December 31, 2027.

Key Details

• Eurobio sale closing date: June 30, 2026; aggregate purchase price received: $171.7 million (cash), subject to adjustments.
• Naveris acquisition closing date: July 1, 2026; initial cash consideration: $161.8 million, subject to adjustments for cash, indebtedness, transaction expenses and net working capital.
• Additional contingent consideration: up to $100.0 million tied to revenue milestones for FY2026 and FY2027.
• CareDx furnished press releases announcing each closing (Eurobio press release Exhibit 99.1; Naveris press release Exhibit 99.2). Purchase/Merger agreements were previously filed as exhibits to earlier 8-Ks.

Why It Matters

• The Eurobio sale and Naveris purchase are material balance-sheet and strategic transactions: CareDx received cash from the divestiture ($171.7M) while spending cash to acquire Naveris ($161.8M plus potential earnouts).
• The transactions may affect CareDx’s cash position and future revenue depending on closing adjustments and Naveris’ achievement of earnout milestones. Investors should review the referenced agreements and future filings (including Naveris financial statements to be filed) for full financial impact and integration plans.